Better diagnostic tools are needed to combat the ongoing COVID-19 pandemic. Here, to meet this urgent demand, we report a homogeneous immunoassay to detect IgG antibodies against SARS-CoV-2. This serological assay, called SATiN, is based on a tri-part Nanoluciferase (tNLuc) approach, in which the spike protein of SARS-CoV-2 and protein G, fused respectively to two different tNLuc tags, are used as antibody probes. Target engagement of the probes allows reconstitution of a functional luciferase in the presence of the third tNLuc component. The assay is performed directly in the liquid phase of patient sera and enables rapid, quantitative and low-cost detection. We show that SATiN has a similar sensitivity to ELISA, and its readouts are consistent with various neutralizing antibody assays. This proof-of-principle study suggests potential applications in diagnostics, as well as disease and vaccination management. Serological tests are important diagnostic and disease surveillance tools for addressing the COVID-19 pandemic. Here, the authors present a tri-part Nanoluciferase based assay to detect antibodies against SARS-CoV-2.
【저자키워드】 SARS-CoV-2, Diagnostic markers, Assay systems, 【초록키워드】 serological test, vaccination, antibody, COVID-19 pandemic, diagnostic, diagnostics, ELISA, Spike protein, Protein, immunoassay, sensitivity, IgG antibody, Serological tests, Serological assay, IgG antibodies, management, target, Disease surveillance, disease, Quantitative, nanoluciferase, principle, patient sera, probes, luciferase, protein G, SATiN, probe, approach, performed, detect, functional, the spike protein, homogeneous, Better, fused, neutralizing antibody assays, 【제목키워드】 antibody, homogeneous,